News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

California Stem Cell, Inc. Submits FDA Phase III Clinical Trial Protocol for the Treatment of Metastatic Melanoma


7/26/2013 10:18:04 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (“CSC”) announced today the submission of a Phase III protocol to the U.S. Food and Drug Administration (“FDA”) for a randomized, double-blind study in metastatic melanoma. The multicenter trial will examine the effectiveness of CSC’s patient specific cancer immunotherapy in patients with recurrent stage III or stage IV metastatic melanoma.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES